

4DMedical presents purpose-built 4D lung scanner for its XV Technology

18 March 2022

Highlights

- 4DMedical gives invited guests a first look at an operational XV Scanner incorporating the Company's proprietary XV Technology™ software
- The XV Scanner has been installed in the Research Imaging NSW facility at the Prince of • Wales Hospital in Randwick
- The XV Technology™ software is already being commercialised, while the scanner • remains on track for clinical deployment in late calendar 2023
- To watch a video of the event attended by Federal Minister for Health and Aged Care, • the Honourable Greg Hunt MP, please click here: https://youtu.be/-rJW0qm-YVQ

Melbourne, Australia, 18 March 2022: Global medical technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") is proud to announce the unveiling of its XV Scanner, the world's first dedicated lung scanner, in a ceremony involving a select group of dignitaries.

This revolutionary piece of Australian-developed medical technology has been installed in the Research Imaging NSW facility at the Prince of Wales Hospital in Randwick. The XV Scanner, which integrates 4DMedical's XV Technology™, represents a significant step forward in lung diagnostics. For the first time ever, it enables highly detailed maps of pulmonary function to be created from a scan that is captured in less than 10 seconds and delivers less radiation than a single chest X-ray.

A presentation given by 4DMedical's Founder and CEO Dr Andreas Fouras at this ceremony highlighted that the advantages of the scanner extend beyond its rich diagnostic power. Coupled with 4DMedical's XV Technology™, the device provides detailed quantitative data on respiratory function via an automated process, which delivers important advantages in other areas as well, including:

- Rapid scan times, which improve patient experience and also deliver increased throughput, thereby improving the economics for healthcare providers; and
- Increased access to XV Technology[™] for more patients, including children, the elderly and the very unwell.

The future of lung health

Melbourne 7/700 Swanston Street, Carlton, Victoria, 3053 Tel: +61 (3) 9545 5940

Los Angeles 21600 Oxnard Street #300, ABN: 31 161 684 831 Tel: +1 (818) 794-6467

4DMedical Limited Woodland Hills, 91367, CA Email: info@4DMedical.com 4DMedical.com

The XV Scanner will support software commercialisation

The successful placement of the scanner at the Prince of Wales Hospital means 4DMedical has designed, built and deployed the first XV Scanner in an Australian hospital within 12 months of MRFF funding, meeting the ambitious target communicated to the market at the time. Importantly, engineering research and development has been completed in-house and within budget, resulting in the creation of a significant body of intellectual property.

4DMedical is now working with leading medical researchers to progress a series of clinical trials that will take the XV Scanner towards regulatory clearance by late 2023. Success here will give 4DMedical a superior product offering accelerating penetration of the global respiratory diagnostic market currently valued at more than US\$31 billion per annum.

4DMedical CEO & Founder Dr Andreas Fouras, said: "The XV Scanner represents a transformative moment in lung health history. Today's unveiling is a major milestone in our XV Technology™ platform's path to commercialisation. It is fitting that the Federal Minister of Health and Aged Care was here for today's ceremony, as the Government's landmark Medical Research Future Fund provided valuable funding for the development phase of our XV Scanner. We look forward to progressing the product through clinical trials whilst also exploring early commercialisation opportunities."

Federal Minister for Health and Aged Care, the Honourable Greg Hunt MP, said: "Every Australian should be proud of this ground-breaking Australian-made medical technology platform. The development of the XV Scanner is a wonderful example of Australia again punching above its weight in the world of health and medical research. Our Government continues to provide unprecedented support to health and medical research, as we back our best and brightest researchers to transform today's ideas into breakthrough treatments for the patients of tomorrow."

A link to the press release by the Federal Minister for Health and Aged Care, titled 'World's first lung scanner to change millions of lives', which covers his appearance at the unveiling of the 4DMedical Scanner, follows: Federal Minister for Health and Aged Care Press Release





Appendix 1: Image from event on Thursday 17 March 2022

4DMedical CEO & Founder Dr Andreas Fouras (left) and Federal Minister for Health and Aged Care, the Honourable Greg Hunt MP (right) at Prince of Wales Hospital, Sydney to unveil 4DMedical's XV Scanner (pictured) on Thursday 17 March 2022

Appendix 2: Video from event on Thursday 17 March 2022

To watch a video of the 4DMedical event attended by Federal Minister for Health and Aged Care, the Honourable Greg Hunt MP please click here: <u>https://youtu.be/-rJW0qm-YV0</u>

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate Charlene Stahr Company Secretary companysecretary@4dmedical.com Media Julia Maguire + 61 2 8999 3699 julia@thecapitalnetwork.com.au



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[™], 4DMedical enables physicians to understand regional airflow in their patients' lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[™]), which is the first and only modality that can dynamically quantify ventilation in 4D. It additionally exposes the patient to lower levels of radiation relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS[™] reports are prepared utilising 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's own revolutionary XV Scanner.

To learn more, please visit: <u>www.4dmedical.com</u>